(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 July 2004 (29.07.2004)

PCT

(10) International Publication Number
WO 2004/063198 A1

(51) International Patent Classification[7]: C07D 487/06, A61P 35/00, A61K 31/55

(21) International Application Number: PCT/IB2004/000026

(22) International Filing Date: 5 January 2004 (05.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/439,396 9 January 2003 (09.01.2003) US

(71) Applicant *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **NINKOVIC, Sacha** [CA/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **BENNETT, Michael, John** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **RUI, Yuanjin** [CN/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **WANG, Fen** [CN/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **BENEDICT, Suzanne, Pritchett** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **TENG, Min** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agents: **LUMB, J., Trevor** et al.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ07950 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/063198 A1

(54) Title: DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS



(I)

(57) Abstract: Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R^2, R^3 and R^4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions, such as cancers.